From the Journals

Telehealth services tied to a major reduction in opioid overdose deaths


 

FROM JAMA PSYCHIATRY

An important engagement tool

A number of questions about telehealth care for OUD remain, including whether increased access to care accounts for the reduction in drug overdose risk that the investigators found or whether other factors are at play.

“There is still more we need to understand about telehealth, such as the quality of care provided and the particular aspects of care provided by telehealth and how this influences health outcomes,” Dr. Jones said.

The results also suggest treatments for OUD are still not finding their way to patients who might benefit, he added.

“Despite the positive findings and the prior research showing that MOUD is highly effective, we found that only one in five patients received telehealth services and only one in eight received any MOUD. This really underscores the need to expand these services across clinical settings,” he added.

These and earlier findings demonstrate the potential benefits of continuing pandemic-era expansion of OUD-related telehealth services and MOUD access, Dr. Jones said.

In preparation for the end of the public health emergency on May 1, the Drug Enforcement Agency recently released a proposal that would allow providers to prescribe a 30-day supply of buprenorphine, but for patients to receive additional prescriptions, a face-to-face meeting would be required. The proposal has drawn criticism from addiction medicine specialists.

The current study didn’t explore if or how the proposal might affect patients with OUD or whether it could blunt the positive effects of the findings.

“Prior research shows that keeping individuals engaged in treatment, including on medications, is a critical part of reducing the negative health and social impacts of opioid use disorder. Our results suggest that telehealth can be an important tool in helping patients engage in and stay connected in care,” said Dr. Jones.

The study was funded by the Centers for Disease Control and Prevention, the Centers for Medicare & Medicaid Services, and the National Institutes of Health. Dr. Johnson reports no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Joint effort: CBD not just innocent bystander in weed
MDedge Psychiatry
Lack of motivation to change can be deadly
MDedge Psychiatry
Psychoactive supplements: What to tell patients
MDedge Psychiatry
Buprenorphine proves effective for fentanyl users in the ED
MDedge Psychiatry
DEA proposals on telehealth for controlled substances draw fire
MDedge Psychiatry
FDA moves to stop the spread of illicit ‘tranq’ in the U.S.
MDedge Psychiatry
Substance abuse disorders may share a common genetic signature
MDedge Psychiatry
Watch for buprenorphine ‘spiking’ in urine drug tests
MDedge Psychiatry
FDA approves OTC naloxone, but will cost be a barrier?
MDedge Psychiatry
Tranq-contaminated fentanyl now in 48 states, DEA warns
MDedge Psychiatry